3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
aldesleukin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
talazoparib
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
apixaban
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Rivaroxaban
1
Radiotherapy
1
Radiation
1
Papillomavirus Vaccines
1
Paclitaxel
1
Observation
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Heparin, Low-Molecular-Weight
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vaginal Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled